BSS Plus 250
"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
BSS Plus 250 mL
Postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. Their relationship to the use of BSS PLUS has not been established.
Read the BSS Plus 250 mL (balanced salt solution) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 10/30/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional BSS Plus 250 mL Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.